跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 3 小时前AI 评分30

Kamada Ltd. 在以色列推出两款新增生物类似药产品

6-K - KAMADA LTD (0001567529) (Filer)

AI 导读

Kamada Ltd. 宣布在以色列推出两款新增产品,以扩展其生物类似药产品组合。该消息作为附件 99.1 随公司 Form 6-K 提交,并被引用纳入其 Form S-8 注册声明。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the Month of October 2026

Commission File Number 001-35948

Kamada Ltd.

(Translation of registrant’s name into English)

2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

The following exhibit is attached:

99.1   Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 6, 2026 KAMADA LTD.
   
  By: /s/ Nir Livneh
   

Nir Livneh

Vice President General Counsel and Corporate Secretary

2

EXHIBIT INDEX

EXHIBIT NO.   DESCRIPTION
99.1   Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

3

来源:SEC EDGAR · 本站存档